Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Safety and Feasibility Trial Protocol of Metformin in Infants After Perinatal Brain Injury
Sponsor: Boston Children's Hospital
Summary
Infants with hypoxic-ischemic encephalopathy (HIE) are at high risk for neurodevelopmental impairment, despite current standards of care. Adjunctive treatments to promote brain repair are needed. The antidiabetic drug metformin has recently been recognized as a neurorestorative agent, but, to date, has not been used in infants. Herein, the investigator describes a clinical trial with the aim of demonstrating the safety and feasibility of metformin use to improve neurodevelopmental outcomes in infants with HIE.
Key Details
Gender
All
Age Range
3 Months - 6 Months
Study Type
INTERVENTIONAL
Enrollment
30
Start Date
2025-10-01
Completion Date
2029-03-01
Last Updated
2026-02-17
Healthy Volunteers
No
Interventions
Metformin
Metformin will be initiated at 25% of the target dose (4 mg/kg administered twice daily, total daily dose 8 mg/kg) for three weeks. In the absence of adverse effects, metformin dose will be escalated to 50% of the target dose (8 mg/kg administered twice daily for a total daily dose of 16mg/kg) for remaining 3 weeks to minimize potential gastrointestinal upset at higher doses. Parents will be documenting adverse events and performing glucometer checks twice a day for 3 days post dose escalation. Parents will then receive a 6-week supply of metformin at the target dose (16 mg/kg administered twice daily, total daily dose 32 mg/kg). Adverse events will be documented and glucometer checks will be performed twice a day for 3 days following dose escalation.
Locations (1)
Boston Children's Hospital
Boston, Massachusetts, United States